Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

"I shouldn't need a Rosetta Stone to understand your notes." -- Prashant Tailor, MD, of the University of California Los ...

According to national statistics, nearly a quarter of U.S. adults ages 75 and older have heart disease, an umbrella term for a cluster of heart conditions, including coronary artery disease and heart ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), ...

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased ...